OncoSil Medical secures a spot in the PALACROS consortium, advancing its OncoSil™ device through a cost-efficient Phase II trial targeting unresectable locally advanced pancreatic cancer.
- Selected for PALACROS consortium in Europe
- PULSE Phase II trial evaluates repeat OncoSil™ treatment
- Trial covers 120 patients across five centres
- In-kind device provision saves approximately $9 million
- Data aims to support regulatory and commercial adoption
OncoSil Medical Enters Major European Pancreatic Cancer Research Consortium
OncoSil Medical (ASX:OSL) has been tapped to join PALACROS, a prominent European academic consortium dedicated to improving treatment outcomes for patients with unresectable locally advanced pancreatic cancer (LAPC). This inclusion signals growing independent recognition of OncoSil’s targeted radiotherapy device as a potential cornerstone in multimodal treatment strategies.
PALACROS, funded by the European Union’s Horizon Europe program, unites leading cancer centres, researchers, and industry partners to establish evidence-based, surgery-centred care protocols. The consortium’s ambition to set a new European standard for LAPC care aligns with OncoSil’s mission to deliver targeted intratumoural radiation therapy that spares surrounding organs.
PULSE Trial to Evaluate Repeat OncoSil™ Treatment with Significant Cost Efficiency
OncoSil Medical will participate through the PULSE Trial, a Phase II randomised study enrolling 120 patients across five European sites. The trial compares single versus repeat OncoSil™ device implantations every three months in patients with unresectable, non-progressive LAPC after induction chemotherapy. Key endpoints include local progression-free survival at nine months, overall survival, quality of life, and conversion to surgery.
Crucially, the OncoSil™ devices will be provided in-kind by the company, with all other trial costs covered by the sponsor. This arrangement is expected to save OncoSil an estimated $9 million compared to a company-sponsored study of similar scale, allowing the company to expand its clinical evidence base without the usual financial burden.
Strategic Implications for Commercial and Regulatory Progression
Access to clinical data generated through PULSE offers OncoSil Medical regulatory and commercial advantages. Should the trial demonstrate positive outcomes, the data could bolster submissions to regulators and payers, accelerating clinical adoption across relevant markets. Additionally, successful trial results may increase OncoSil™ device utilisation, creating a revenue multiplier effect as patient treatment volumes grow.
This trial builds on OncoSil’s prior clinical studies such as TRIPP-FFX, PANCOSIL, and PANCO, further validating its approach. The consortium’s focus on innovative local therapies underscores the strategic importance of OncoSil’s technology in improving local tumour control and expanding surgical candidacy.
OncoSil’s CEO Nigel Lange emphasised the significance of joining PALACROS, highlighting the opportunity to evaluate repeat treatment in a robust academic setting and contribute to one of Europe’s largest pancreatic cancer research efforts.
Bottom Line?
OncoSil’s integration into PALACROS and the cost-effective PULSE trial could accelerate its clinical validation and commercial uptake, but ultimate impact hinges on forthcoming trial results.
Questions in the middle?
- Will the PULSE Trial’s repeat treatment approach significantly improve survival and surgical conversion rates?
- How quickly will clinical data from PULSE translate into regulatory approvals and reimbursement decisions?
- Can OncoSil leverage PALACROS participation to expand its footprint beyond Europe into other key markets?